We are live on ! Find out more
ORIA

Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA

Delisted

ORIA was delisted on the 28th of April, 2023.

Back to rankings

48 hedge funds and large institutions have $132M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

17% more funds holding

Funds holding: 41 → 48 (+7)

4% more capital invested

Capital invested by funds: $127M → $132M (+$4.67M)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

Holders
48
Holders Change
+7
Holders Change %
+17.07%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
8
Closed
2
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
+$2K

Top Buyers

Rank Fund Capital Flow
1
HSBC Holdings
HSBC Holdings
United Kingdom
+$6.43M
2
CF
Cantor Fitzgerald
New York
+$1.95M
3
TCA
Taconic Capital Advisors
New York
+$1.9M
4
FTCM
First Trust Capital Management
Illinois
+$1.71M
5
Millennium Management
Millennium Management
New York
+$500K

Top Sellers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
-$6.43M
2
ACA
Arena Capital Advisors
California
-$2.47M
3
FTCM
Fir Tree Capital Management
New York
-$485K
4
FLC
Fifth Lane Capital
Texas
-$326K
5
EAM
Exos Asset Management
New York
-$92.7K

ORIA Hedge Fund Activity: Q2 2022 in Review

48 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q2 2022, worth a combined $132M — up 3.7% from $127M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ORIA positions and 2 closed out — a net gain of 7 holders — while 7 added to existing stakes and 8 trimmed.

The largest buyer was HSBC Holdings, opening a new position worth an estimated $6.43M. The largest seller was Linden Advisors, cutting an estimated $6.43M.

  • 48 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q2 2022, up from 41 in Q1 2022.
  • Funds reported $132M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q2 2022, up 3.7% quarter-over-quarter.
  • 9 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q2 2022 and 2 closed out, a net change of +7 holders.
  • The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q2 2022 was HSBC Holdings, an estimated $6.43M added.
  • The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q2 2022 was Linden Advisors, an estimated $6.43M sold.

Based on aggregated 13F filings for Q2 2022.